

NEUROHEALING

NeuroHealing Pharmaceuticals Inc.

Industry Leaders Select NeuroHealing's NH001 Among Top Ten Most Promising Neuroscience Projects Available For Partnering

Media Advisory

NEWTON, Mass./EWORLDWIRE/Aug. 11, 2008 --- NeuroHealing Pharmaceuticals, a private clinical stage company developing products for individuals with chronic brain injuries and neurodegenerative diseases, today announced that NH001 has been chosen by Windhover Information and independent expert Harry Tracy as one of the top 10 most interesting neuroscience projects in development available for strategic partnering. NH001 is in clinical development to improve the functional outcome of patients in a vegetative state or minimally conscious state following a severe traumatic brain injury.

"Selected companies were evaluated using a strict set of judging criteria and represent what our committee considered the most attractive neuroscience opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "Winners have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities, potential for new opportunities beyond initial indications and corporate stability."

The selection was made by Windhover Information in conjunction with Harry M. Tracy, Ph.D., President of NeuroInvestment Research. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. NeuroInvestment Research (www.niresearch.com) is a leading independent analyst firm focusing exclusively on neurological and psychiatric drug development. As a selected company, NeuroHealing has been invited to present the NH001 partnering opportunity at Windhover's Therapeutic Area Partnerships conference on November 3-5, 2008 in Philadelphia.

About NH001

NH001 is a potent, direct-acting, dopaminergic agonist with well-established human safety data, which rapidly crosses the blood brain barrier. Because dopaminergic function appears to be of importance in executive central nervous system function, such as arousal and memory, NH001 has been designed to help regain consciousness, accelerate recovery and improve the functional outcome of patients from a coma, vegetative or minimally conscious state following a traumatic brain injury.

NH001 has been tested in an open label trial in patients with a traumatic brain injury who were in a vegetative or minimally conscious state for 1-4 months and neurologically stable for weeks prior to beginning NH001 treatment. The responses to NH001 were rapid, observed in the first 2-4 weeks and maintained after NH001 discontinuation. NH001 treatment was well tolerated.

NeuroHealing has an open IND from the FDA to conduct a double blind Phase II clinical trial, which will be initiated at the Spaulding Rehabilitation Hospital (Harvard Medical School affiliate) in Boston under funding by a clinical grant from the FDA's Office of Orphan Drug Products.

About Windhover

Windhover Information Inc. (<http://www.windhover.com>), an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars.

About NeuroHealing Pharmaceuticals

NeuroHealing Pharmaceuticals Inc. (<http://www.NeuroHealing.com>) is a clinical stage company developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system. Programs include:

- . NH001, a dopaminergic agent in Phase II testing to help post traumatic brain injury patients to emerge from a coma, vegetative or minimally consciousness state
- . NH004, an anticholinergic agent in a convenient intra-orally dissolving film in Phase II testing to help treat Parkinsons and motor neuron patients who suffer from sialorrhea (drooling)
- . NH02D, a novel mechanism compound to accelerate the rehabilitation outcomes of stroke patients who remain with chronic motor and cognitive disabilities.

HTML: <http://www.eworldwire.com/pressreleases/18849>

MOBILE: <http://e4mobile.com/pressreleases/18849>

PDF: <http://www.eworldwire.com/pdf/18849.pdf>

ONLINE NEWSROOM: <http://www.eworldwire.com/newsroom/305366.htm>

LOGO: <http://www.eworldwire.com/newsroom/305366.htm>

CONTACT:

Daniel Katzman
NeuroHealing Pharmaceuticals
PHONE. 6173314111
<http://www.NeuroHealing.com>

KEYWORDS: NeuroHealing Pharmaceuticals Inc., Neuroscience pharmaceutical partnering, neuroscience research, neuro-rehabilitation process, functional outcome, debilitating brain injuries, Clinical stage programs, NH001, dopaminergic agent, post traumatic brain injury, coma, vegetative, minimally consciousness state, NH004, anticholinergic agent intra-orally muco-adhesive dissolving film, treat motor neuron disease, sialorrhea, drooling, NH02D, mechanism compound, rehabilitation, stroke, chronic motor, cognitive disabilities

SOURCE: NeuroHealing Pharmaceuticals